Brought to you by 
GSK teams up with FivePrime for muscle disorder therapeutics
16 Apr 2021
Executive Summary
GlaxoSmithKline PLC has licensed exclusive rights to FivePrime Therapeutics Inc.'s (protein and antibody therapeutics) secreted proteins and transmembrane receptor proteins to treat sarcopenia, cachexia, and other skeletal muscle disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK teams up with FivePrime for muscle disorder therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice